Search the Newsreel

Gildan Activewear Inc. (GIL) Shares Tumble 18% Amid Activist Forensic Report Challenging Company's Business Practices And Potentially Improper Revenue Recognition -- HBSS

Gildan Activewear Inc. (GIL) shares plummeted 18% after Jehoshaphat Research published a forensic report alleging improper channel stuffing and revenue recognition practices. This report, based on interviews with former employees and customers, wiped out $2.15 billion from Gildan's market capitalization. Hagens Berman has launched …

ETFs Investing in Gildan Activewear Inc. Stocks

This article lists Exchange Traded Funds (ETFs) that hold stocks of Gildan Activewear Inc. It provides a table detailing various ETFs, including their market value, weight of Gildan Activewear Inc. stock, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, relative …

Is Gilead Sciences (GILD) Fully Valued Following Mixed Earnings And A Full Year EPS Miss?

Gilead Sciences (GILD) reported mixed Q2 earnings with revenue up 4.4% to $6.96 billion but missed full-year EPS estimates. While one valuation narrative suggests Gilead is 6.2% overvalued at $136.30 with a fair value of $128.38, another Discounted Cash Flow (DCF) model indicates it …

Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on July 15, 2026, for approximately $390,000, under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Dickinson still directly holds 168,646 shares. The sale was executed at an average …

Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 69/100

Gilead Sciences Inc (GILD) saw its stock price rise by 3.5% on July 16, 2026, reaching $136.30. Despite this gain, GuruFocus's GF Value™ estimates the stock to be significantly overvalued at $96.17, implying a 41.7% premium. The GF Score™ of 69/100 suggests above-average performance …

Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan

Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences (NASDAQ: GILD), reported an open-market sale of 3,000 shares of common stock on July 15, 2026, at an average price of $129.9192 per share. This sale was conducted under a Rule 10b5-1 trading …

Gilead Sciences chief comm & corp aff officer sells $389,757 in stock

Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), sold 3,000 shares of company stock for approximately $389,757 on July 15, 2026, as part of a pre-arranged trading plan. Despite the sale, the stock is considered potentially undervalued according to InvestingPro …

Ermenegildo Zegna (NYSE:ZGN) Shares Up 6.6% - Should You Buy?

Ermenegildo Zegna (NYSE:ZGN) shares increased by 6.6% on Thursday, reaching $14.33 with higher-than-average trading volume, indicating renewed investor interest. Wall Street analysts have a "Moderate Buy" consensus rating with an average target price of $13.01, though some recent insider selling by the director and …

Gildan (GIL) Stock Plummets Over 18% Amid Fraud Allegations

Gildan Activewear Inc. (GIL) saw its stock price drop over 18%, losing approximately $2.15 billion in market value, following fraud allegations from Jehoshaphat Research. The report accuses Gildan of "channel stuffing" and using financial engineering to hide negative organic growth. Despite a GF Value™ …

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences (GILD) has garnered investor attention, with its stock performing well recently. The article discusses factors influencing its future performance, including revisions to earnings estimates, projected revenue growth, past financial results, and valuation metrics. Zacks currently rates Gilead as a Zacks Rank #3 …

Gildan Activewear Announces Date for Second Quarter 2026 Financial Results

Gildan Activewear Inc. (GIL) will release its 2026 second quarter financial and operating results on Thursday, July 30, 2026. A press release will be issued before markets open, followed by a conference call at 8:30 AM ET to discuss the results with financial analysts …

Bragar Eagel & Squire, P.C. is Investigating Gildan

Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Gildan Activewear Inc. (NYSE:GIL) on behalf of its stockholders. The investigation follows a short report published by Jehoshaphat Research alleging that Gildan has engaged in financial engineering to hide …

Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier

Gilead Sciences, Inc. (NASDAQ: GILD) shareholder Johanna Mercier plans to sell 3,000 common shares through Morgan Stanley Smith Barney LLC on July 15, 2026, for an aggregate value of approximately $389,757.60. These shares were acquired as performance shares on February 4, 2025. Mercier has …

Form 144 GILEAD SCIENCES For: 15 July By Investing.com

This article announces the filing of Form 144 for Gilead Sciences (GILD) on July 15. The brief notification is presented without further details but is relevant for investors tracking insider transactions. Gilead Sciences' stock is also noted with a 1.28% increase.

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced "death crosses" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% dividend yield, …

Gildan Schedules July 30 Call After Q2 Results Release

Should Gilead’s Revenue Beat but Softer EPS Outlook Require Action From Gilead Sciences (GILD) Investors?

Gilead Sciences reported a Q3 revenue beat of US$6.96 billion, exceeding analysts' expectations by 1.5%, but concurrently issued a softer full-year earnings-per-share outlook. This outcome suggests that while sales are strong, the company faces challenges in translating this growth into sustained profitability, raising questions …

Ermenegildo Zegna N.V. (ZGN) Q4 2025 Earnings: EPS Surges Past Expectations, Stock Edges Higher - Forward Guidance Trends

$GIL Notification: Gildan Investigated for Misrepresentations about its Revenue Sources after 18% Stock Drop

GILD Prognose — Kursziel für 2027

Ermenegildo Zegna NV (ZGN) faces earnings with its 52-week trend active

Heavy participation and a sharp multiweek advance have raised the setup risk around the luxury apparel maker’s June report.

Goldman Sachs downgrades Ermenegildo Zegna stock rating to neutral

T-shirt maker Gildan plunges on short seller’s revenue claim

Ermenegildo Zegna NV (ZGN) draws heavier turnover before earnings

The apparel manufacturer’s four-week rally is meeting a June 19 results date with stronger participation, while Relative Strength remains a constraint.

Should You Investigate Ermenegildo Zegna N.V. (NYSE:ZGN) At US$14.70?

Ermenegildo Zegna (ZGN) Gains 2.6% as Luxury Sector Shows Resilience - Momentum Trade

Ermenegildo Zegna (ZGN) Stock Hovers Near Support Amid Modest Decline - Volatility Stop

Why Did TSX:GIL - Gildan Activewear Fall Today Despite Strong Apparel Demand and Dividend Stability in May 2026?

Ermenegildo Zegna: Solid Execution But Full Valuation, We Remain Neutral (NYSE:ZGN)

There May Be Reason For Hope In Gildan Activewear's (TSE:GIL) Disappointing Earnings

Gildan Activewear: Look Beyond Proforma Revenue Contraction (NYSE:GIL)

What Gildan Activewear (TSX:GIL)'s Record Q1 Sales and HanesBrands-Driven Loss Mean For Shareholders

Gildan Earnings: Expectations Exceeded as Hanesbrands Integration Underway

After buying HanesBrands, Gildan posts $1.17B quarter and keeps outlook

Gildan Activewear (GIL) Q1 Earnings and Revenues Surpass Estimates

Earnings call transcript: Gildan Activewear beats Q1 2026 forecasts, stock rises 6.22%